Navigation Links
Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
Date:9/7/2007

- First Patient Enrolled in Second of Two Phase 3 Trials

- More Than 100 Patients Enrolled in First Phase 3 Trial - Trial Design Was Reviewed Under Special Protocol Assessment Procedure

With The FDA

IRVINE, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) today announced today that it has begun enrolling patients in its second pivotal Phase 3 registrational trial for EOquin, the Company's drug candidate for non-invasive bladder cancer. The trial design was reviewed under a previously announced Special Protocol Assessment procedure, which calls for two double-blind, placebo-controlled, randomized clinical trials.

"The initiation of our second pivotal Phase 3 trial for EOquin in non-invasive bladder cancer patients demonstrates the significant progress we are making with this program," stated Rajesh C. Shrotriya, M.D., Chairman, President and CEO of Spectrum Pharmaceuticals. "Non-invasive bladder cancer is the fifth most common cancer, with a incidence of more than 67 thousand in the U.S. and more than 147 thousand in Europe. Because bladder cancer is typically not lethal, it is estimated that there are more than 500 thousand people suffering from bladder cancer in the United States and more than 935 thousand in Europe. If approved, EOquin may help the many patients suffering from this disease."

The EOquin study calls for two double blind, placebo-controlled, randomized Phase 3 clinical trials, in patients with non-invasive bladder cancer. Patients will be randomized in a one-to-one ratio to EOquin or placebo. The primary endpoint will be the difference in the rate of tumor recurrence between the two treatmen
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tech Digest: Firstlogic, Fiserv, Red Prairie, Spectrum Brands, Associated Bank
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A
5. In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate
6. CIOs looking to hire more IT workers in second quarter
7. DNASTAR catches second wave of sequencing
8. 9 tips for making 90 seconds count in an investment pitch
9. City of Hope adds second TomoTherapy system
10. UW-Madison hybrid-vehicle team places second nationally
11. Just one nanosecond: Clocking events at the nanoscale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... , Sept. 15, 2014  FlexTech Alliance ... for flexible, printed product demonstrators (demos) and a ... RFP process with pre-proposals due on October 22, ... Funds for proposals ultimately selected are provided by ... a significant cost share by the proposing organization. ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... interdisciplinary team of researchers led by Northeastern University ... precise inter-nanotube junctions and a variety of nanocarbon ... facile and easily scalable, which will allow the ... networks for use in applications ranging from electronic ... from cars to sports equipment. , Their findings ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... International,Corporation (Nasdaq: PRXL ), a leading ... as a Vice President and General,Manager in ... brings more than 20 years of experience ... position, Ms. Fisher leads a global,team of ...
... Healing ... of Chronic Wounds, ... company focused on improving patient quality of life, today,announced that ... its KFH Novo medical device, a breakthrough medical,technology that enhances ...
... a.m. ET; 8:00 a.m. PT, VANCOUVER and SAN ... MGIFF), a clinical-stage developer of drugs for infectious,diseases, will ... 13,2008 at 11:00 a.m. ET (8:00 a.m. PT) to ... 31, 2008 and provide an update on,company activities. To ...
Cached Biology Technology:PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 2PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 3PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team 4Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device 2
(Date:9/15/2014)... outbreak in West Africa, which has claimed more than ... understanding of the molecular biology of the virus that ... antiviral drugs to treat or prevent Ebola hemorrhagic fever. ... USA under the leadership of Dr Dan Engel, ... has obtained the crystal structure of a key ...
(Date:9/15/2014)... it,s not what comes to mind when you think ... Doncaster,s 310-million-year-old past, including a fossilised shark egg case, has ... the fossilised plants and creatures may even be new to ... crabs and some previously unrecorded seed pods are amongst the ... within the coal and shale deposits in what is one ...
(Date:9/15/2014)... reports about the need for vitamin E and how ... that adequate levels of this essential micronutrient are especially ... who are or may become pregnant. , A lifelong ... said, but often complicated by the fact that this ... through diet alone. It has been estimated that only ...
Breaking Biology News(10 mins):Protein secrets of Ebola virus 2'Jaws' lived in Doncaster 2Vitamin E intake critical during 'the first 1,000 days' 2Vitamin E intake critical during 'the first 1,000 days' 3
... shrimp. Fried eggs. Burgers and fries. New research suggests ... foods are so appealing together. It has been known ... uptake, but fundamental aspects of that process remain poorly understood. ... for Science are using zebrafish to better understand the cellular ...
... People with celiac disease struggle with limited food choices, ... in wheat and other grains. Researchers from the University ... banana flour, which tasters found more acceptable than regular whole ... cheaper to produce than standard pastas. Their research is ...
... first paternity study of southern right whales has found a ... say, which is good news for the overall genetic diversity ... through in-breeding. Results of the study, by researchers at ... Zealand Department of Conservation, have just been published in the ...
Cached Biology News:Zebrafish research shows how dietary fat regulates cholesterol absorption 2Pasta made from green banana flour a tasty alternative for gluten-free diets 2First paternity study of southern right whales finds local fathers most successful 2First paternity study of southern right whales finds local fathers most successful 3
Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
PEG 8000, Molecular Biology Grade...
... Deacetylase (HDAC) Antibody Sampler Kit Kit ... Catalog #2062, 40 ul Histone Deacetylase 3 ... Deacetylase 4 (HDAC4) Antibody, Catalog #2072, 40 ... #2082, 40 ul Histone Deacetylase 6 (HDAC6) ...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: